The 2026 review finds limited support for topical spironolactone in teens with inflammatory acne. Topical spironolactone is spironolactone applied to the skin to block local androgen effects, not the oral tablet. Most studied patients were adult women, formulas varied widely, and benefit points to mild-to-moderate acne rather than severe inflamed breakouts. That gap matters when families compare a compounded product with proven teen options.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the review examine?
- Why is the trial base too small for teens?
- How does topical compare for inflamed lesions?
- Which teen options have stronger backing?
What did the review examine?
The earlier systematic work set a narrow test. According to the 2022 systematic review in the Journal of Dermatology, Wiley reviewers searched PubMed, ClinicalTrials.gov, Cochrane and Google Scholar through March 18, 2022. They included only clinical trials of topical spironolactone for acne and excluded oral spironolactone studies.
The 2026 narrative review in Clinical, Cosmetic and Investigational Dermatology then judged what those trials can prove for teens. It called the topical record limited, heterogeneous and partly indirect. Its read was cautious: possible help for mild-to-moderate acne, not strong proof for severe inflammatory teen acne.
Why is the trial base too small for teens?
The pooled base is tiny. About 195 patients across 5 trials tested topical spironolactone, while another meta-analysis found only 4 trials with 212 patients. Small pools make firm teen conclusions hard. Formulas also differed across trials, not just doses.
Trials used 5% cream, 5% gel, 2% solution, 3% powder and 1% nanogel. Different vehicles absorb differently, so results do not combine cleanly. Age and sex add another limit. Included patients spanned ages 11 to 40 and were mostly women. Teens with inflamed papules, pustules and nodules are poorly represented as a separate group.
How does topical compare for inflamed lesions?
A 2025 meta-analysis of 1,086 patients found 5% topical spironolactone reduced total lesion count and acne severity scores versus placebo after 8 weeks. The same analysis found oral 100 mg improved severity scores more than topical treatment. Short benefit is not equal benefit. Robust inflammatory-lesion testing still centers on oral drugs. The ongoing U.S.
SD-ACNE trial randomizes patients to spironolactone 100 mg per day versus doxycycline 100 mg per day for 16 weeks. Its main outcome is absolute inflammatory-lesion-count reduction. That design highlights the mismatch. Oral spironolactone faces a direct antibiotic comparison on inflamed counts. Topical spironolactone has no similar large inflammatory-acne trial.
Which teen options have stronger backing?
According to the 2024 American Academy of Dermatology guidelines, dermatology guidelines strongly recommend topical benzoyl peroxide, retinoids and antibiotics for acne. The guidelines only conditionally recommend oral spironolactone and make no recommendation for topical spironolactone. For a teen visit, that distinction is practical.
Teens also have an approved topical antiandrogen choice. Clascoterone 1% cream is for patients 12 years and older, while topical spironolactone remains off-label compounded use based on prescriber judgment. Miiskin prescribing information states the compounded cream, gel or solution is not FDA-approved and lacks FDA review for acne safety, effectiveness or comparison with oral spironolactone. Families can use that contrast to ask focused questions:.
- Does my teen have mild-to-moderate or severe inflammatory acne?
- Which guideline-backed topical fits first: benzoyl peroxide, retinoid, antibiotic or clascoterone?
- If spironolactone is discussed, why topical rather than studied oral use?
- What follow-up count will judge inflamed lesions in 8 to 12 weeks?
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: Study Design and Evidence Limits for Teens With Inflammatory Acne
- Topical Clascoterone Evidence Revisited in 2026: Study Design and Evidence Limits for Teens With Inflammatory Acne
- Spironolactone, Metformin, and Bicalutamide for Acne in a 2026 Review: What the Findings Mean for Teens With Inflammatory Acne